SYFOVRE
Search documents
Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS
Businesswire· 2026-04-01 02:08
Core Viewpoint - Kahn Swick & Foti, LLC is investigating the proposed sale of Apellis Pharmaceuticals, Inc. to Biogen Inc. to assess the adequacy of the price and process involved in the transaction [1]. Summary by Relevant Sections - **Proposed Transaction Details** - Apellis shareholders are set to receive $41.00 per share in cash along with a nontransferable contingent value right for two additional payments of $2.00 per share, contingent on meeting specific annual global net sales thresholds for SYFOVRE [1]. - **Investigation Purpose** - The investigation aims to determine whether the proposed consideration undervalues Apellis Pharmaceuticals and whether the process leading to this valuation was adequate [1]. - **Contact Information for Investors** - Investors who believe the transaction undervalues the company can contact Kahn Swick & Foti, LLC for further discussion regarding their legal rights [2].
Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio
Yahoo Finance· 2026-03-31 16:20
Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio Proactive uses images sourced from Shutterstock Biogen Inc (NASDAQ:BIIB, XETRA:IDP) will acquire Apellis Pharmaceuticals Inc (NASDAQ:APLS) for $41 per share in cash, in a deal valued at approximately $5.6 billion, it was announced on Tuesday. Apellis shareholders will also receive a nontransferable contingent value right (CVR) worth up to $4 per share if certain global sales milestones for SYFOVRE are achieved. Shares ...
Shareholder Alert: The Ademi Firm investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
Prnewswire· 2026-03-31 16:00
<!doctype html> <!-- For structured data --> <!-- For language declaration --> Shareholder Alert: The Ademi Firm investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders <!-- Additional Authorable Meta tags --> Accessibility StatementSkip NavigationMILWAUKEE, March 31, 2026 /PRNewswire/ -- Ademi LLP is investigating Apellis (NASDAQ: APLS) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Biogen.Click here ...
Apellis Shares Surge 135% After Acquisition Agreement With Biogen
RTTNews· 2026-03-31 14:41
Apellis Pharmaceuticals, Inc. (APLS) shares surged 135.69 percent, up $23.19 to $40.28 on Tuesday, after Biogen Inc. (BIIB) agreed to acquire all outstanding Apellis shares for $41.00 per share in cash, valuing the deal at approximately $5.6 billion. Apellis shareholders will also receive a nontransferable contingent value right that could deliver two additional $2 per share payments tied to annual global net sales targets for SYFOVRE.The stock is currently trading at $40.28, sharply above its previous clo ...
Biogen (NasdaqGS:BIIB) Earnings Call Presentation
2026-03-31 12:30
March 31, 2026 BIOGEN PROPOSED ACQUISITION OF APELLIS INVESTOR WEBCAST FORWARD-LOOKING STATEMENTS These statements speak only as of the date of this presentation and the discussions during this conference call and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cau ...
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
Globenewswire· 2026-03-31 10:59
Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved in geographic atrophy, an immune-mediated retinal diseaseBringing together Biogen and Apellis’ commercialization capabilities will maximize the potential of both EMPAVELI® and SYFOVRE®, while Apellis’ talent and expertise will accelerate Biogen’s entry into nephrology and augment launch readiness for felzartama ...
Apellis Pharmaceuticals, Inc. (APLS) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Seeking Alpha· 2026-03-02 17:57
Core Insights - The company is focusing on building a strong foundation for future growth, emphasizing the importance of the current year for its strategic development [1] - The organization has established three main pillars, with a focus on providing a best-in-class therapy for patients with geographic atrophy through SYFOVRE [1] - There is an ongoing developmental program that combines a subcutaneous siRNA against C3 with intravitreal injection of SYFOVRE, with data readouts expected next year [1] Product Launch and Market Penetration - The company is in the midst of an exciting launch for EMPAVELI, achieving over 5% market penetration in Q4 among an estimated 5,000 patients with C3G and IC-MPGN [2]
Apellis Pharmaceuticals (NasdaqGS:APLS) FY Conference Transcript
2026-03-02 15:52
Summary of Apellis Pharmaceuticals FY Conference Call Company Overview - **Company**: Apellis Pharmaceuticals (NasdaqGS:APLS) - **Key Products**: SYFOVRE and EMPAVELI - **Focus Areas**: Geographic atrophy, C3G, IC-MPGN, and gene editing programs Core Points and Arguments Business Strategy and Strengths - Apellis has established a strong foundation with three main pillars: SYFOVRE, EMPAVELI, and a gene editing program in collaboration with Beam [2][4] - SYFOVRE is positioned as a best-in-class therapy for geographic atrophy, with ongoing development of a combination therapy using siRNA against C3 [2] - EMPAVELI is experiencing a strong launch, with over 5% penetration in the C3G and IC-MPGN market, targeting a potential 50% penetration at peak [3][6][35] Revenue Performance - Revenue declined year-over-year due to unique factors, including flat revenue from EMPAVELI's initial indication (PNH) and challenges faced by SYFOVRE [5][10] - The decline was attributed to the loss of patient co-pay assistance, leading to treatment discontinuation and a shift to less effective therapies [7][8] - Despite these challenges, there was a 17% growth in injections for geographic atrophy, indicating underlying demand [9] Market Dynamics - SYFOVRE's market share has remained stable at approximately 60%, with a 50/50 split for new patient enrollments [18] - The introduction of a prefilled syringe is expected to enhance market penetration and ease of administration [14] - The retina community is increasingly recognizing the importance of SYFOVRE, especially with new data showing significant benefits for patients [13] Competitive Landscape - Apellis believes SYFOVRE has a superior efficacy profile compared to competitors, supported by robust data from clinical trials [20][21] - EMPAVELI is the only product approved for pediatric use and post-transplant patients, differentiating it from competitors [31] - Safety profile of EMPAVELI is strong, with no cases of encapsulated meningococcal infection reported despite expectations based on class effects [32] Future Outlook - Apellis aims to achieve profitability with a solid cash position of $466 million, bolstered by expected milestone payments [44] - The company projects significant revenue growth, with expectations of reaching $1.7 billion by 2030 [47] - Upcoming data readouts from clinical trials, particularly for the gene editing program, are anticipated to drive future growth [42] Additional Important Insights - The company is focused on redefining treatment for geographic atrophy and addressing the unmet needs in the wet AMD market, which is valued at $12 billion [26] - The potential for EMPAVELI in FSGS and DGF is significant, with a combined epidemiology of approximately 33,000 patients in the U.S. [35][36] - The company is committed to continuous improvement in patient treatment experiences and outcomes, leveraging innovative technologies like functional OCT [15][16] This summary encapsulates the key points discussed during the Apellis Pharmaceuticals FY Conference Call, highlighting the company's strategic direction, market performance, and future growth potential.
Apellis Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary
Yahoo Finance· 2026-02-24 21:31
Core Insights - The company characterizes 2025 as a foundational year focused on disciplined execution and the central role of C3 inhibition to address complement-driven diseases in ophthalmology and nephrology [1] Performance Overview - SYFOVRE shows resilient performance in geographic atrophy (GA) with a 17% year-over-year growth in total injections, despite revenue being impacted by elevated free goods utilization [1] - The launch of EMPAVELI in C3G and primary IC-MPGN is identified as a primary near-term growth engine, achieving over 5% market penetration in its first full quarter, which management claims outpaces other rare nephrology launches [1] Strategic Positioning - The strategic positioning for SYFOVRE is shifting towards 'renewed growth' in 2027, supported by the introduction of a prefilled syringe and AI-enabled functional imaging (OCT-F) to enhance practice workflow and patient visualization of benefits [1] Financial Strategy - The company emphasizes a transition towards self-funding its pipeline, supported by a growing commercial revenue base and a disciplined approach to operating expenses [1] - Management attributes the strong uptake of EMPAVELI to its status as the only approved therapy for approximately two-thirds of the targeted patient population, including pediatric and post-transplant segments [1]
Apellis Pharmaceuticals (APLS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
ZACKS· 2026-02-24 17:01
Core Insights - Apellis Pharmaceuticals reported a revenue of $199.91 million for the quarter ended December 2025, which is a decrease of 5.9% compared to the same period last year [1] - The company's EPS was $0.47, a significant improvement from -$0.29 in the year-ago quarter, indicating a positive earnings surprise of +219.14% against a consensus estimate of -$0.40 [1] Revenue Breakdown - Product revenue, net was $190.34 million, slightly above the average estimate of $187.07 million by nine analysts, representing a year-over-year change of -0.4% [4] - Licensing and other revenue amounted to $9.57 million, exceeding the nine-analyst average estimate of $7.31 million, but showing a significant year-over-year decline of -55.2% [4] - Product Revenue from EMPAVELI was reported at $35.1 million, surpassing the eight-analyst average estimate of $28.51 million, reflecting a year-over-year increase of +50.3% [4] - Product Revenue from SYFOVRE was $155.2 million, slightly above the eight-analyst average estimate of $154.18 million, but down by -7.5% compared to the previous year [4] Stock Performance - Over the past month, shares of Apellis Pharmaceuticals have returned +2.2%, contrasting with a -1% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]
